← Back to Analyst Consensus 
AXSM Buy
Axsome Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 28
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 2 reiterations from 2 firms
Next Earnings
Nov 2, 2026 (7 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 8, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Sep 29, 2026 | Deutsche Bank | maintain | Buy → Buy | — | 57% |
| Sep 25, 2026 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | — | 54% |
| Sep 23, 2026 | Truist Securities | maintain | Buy → Buy | — | 54% |
| Sep 18, 2026 | Piper Sandler | reiterate | Overweight → Overweight | — | 54% |
| Aug 31, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 12, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| Aug 11, 2026 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | — | 54% |
| Aug 11, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Aug 11, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Aug 11, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| Aug 11, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Jul 31, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| Jul 21, 2026 | BMO Capital | initiate | — → Outperform | — | 53% |
| Jul 15, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jul 8, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jul 7, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Jun 17, 2026 | TD Cowen | maintain | Buy → Buy | — | 54% |
| May 5, 2026 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | — | 54% |
| May 5, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| May 5, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| May 5, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| May 5, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| May 5, 2026 | Baird | maintain | Outperform → Outperform | — | 55% |
| May 5, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| May 5, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| May 4, 2026 | Jefferies | maintain | Buy → Buy | — | 52% |
| May 4, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| May 1, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Apr 10, 2026 | UBS | maintain | Buy → Buy | — | 54% |
| Mar 25, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Feb 24, 2026 | UBS | maintain | Buy → Buy | $251 | 54% |
| Feb 24, 2026 | Guggenheim | maintain | Buy → Buy | $220 | 52% |
| Feb 24, 2026 | RBC Capital | maintain | Outperform → Outperform | $222 | 55% |
| Feb 24, 2026 | Wells Fargo | maintain | Overweight → Overweight | $202 | 54% |
| Feb 24, 2026 | Wolfe Research | initiate | — → Outperform | $230 | 53% |
| Feb 23, 2026 | Needham | reiterate | Buy → Buy | $225 | 50% |
| Feb 3, 2026 | Jefferies | maintain | Buy → Buy | $245 | 52% |
| Jan 28, 2026 | Leerink Partners | maintain | Outperform → Outperform | $205 | 51% |
| Jan 21, 2026 | RBC Capital | maintain | Outperform → Outperform | $219 | 55% |
| Jan 20, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | $260 | 44% |
| Jan 16, 2026 | Piper Sandler | maintain | Overweight → Overweight | $223 | 54% |
| Jan 13, 2026 | Wells Fargo | maintain | Overweight → Overweight | $193 | 54% |
| Jan 8, 2026 | Morgan Stanley | downgrade | Overweight → Equal-Weight | $204 | 54% |
| Jan 6, 2026 | UBS | maintain | Buy → Buy | $248 | 54% |
| Jan 5, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | $200 | 44% |
| Dec 31, 2025 | Needham | maintain | Buy → Buy | $169 | 50% |
| Nov 6, 2025 | Mizuho | maintain | Outperform → Outperform | $202 | 52% |
| Nov 4, 2025 | Morgan Stanley | maintain | Overweight → Overweight | $196 | 54% |
| Nov 4, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $185 | 44% |
Price Target Trend
Jun 20, 2026 Oct 26, 2026
EPS Estimates
0q —
0y —
+1y —
+1q —
Cross-Platform Signals
No cross-platform signals in the last 90 days